Researchers at Washington University School of Medicine in St. Louis have received a two-year, $5 million grant to offer 50,000 saliva tests for the SARS-CoV-2 virus to students, teachers and staff in the six special education schools operated by the Special School District of St. Louis County (SSD).
Findings indicate anti-inflammatory drugs likely to benefit only a fraction of people with severe disease
A look at how Washington University came together in the spring and summer to respond to the COVID-19 outbreak — and to prepare for a fall semester that is anything but back to normal.
In a preliminary study of COVID-19 patients with mild-to-moderate disease who were attempting to recover in their homes, researchers at Washington University School of Medicine in St. Louis have found that the drug fluvoxamine seems to prevent some of the most serious complications of the illness and make hospitalization and the need for supplemental oxygen […]
New findings from researchers at Washington University School of Medicine in St. Louis suggest the eye’s cornea can resist infection from the novel coronavirus. Although the herpes simplex virus can infect the cornea and spread to other parts of the body in patients with compromised immune systems, and Zika virus has been found in tears […]
Rachel Presti, MD, PHD is the director of Washington University’s Infectious Diseases Clinical Research Unit and principal investigator for WashU’s COVID-19 vaccine trials. Sharon Frey, MD, is clinical director for SLU’s Center for Vaccine Development and principal investigator for SLU’s vaccine trials. Presti and Frey are coordinating so the two institutions can lead different vaccine […]
Lindsay to serve as co-chair for the Patient-Centered Outcomes Research Institute’s (PCORI) Advisory Panel on Rare Diseases, one of five multi-stakeholder advisory panels.
Phase 3 trial involves hospitalized patients with moderate to severe disease